TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
This acquisition enables MTD to open new, strategic markets
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
The facility will manufacture tablets, capsules, and injections for the oncology segment
Subscribe To Our Newsletter & Stay Updated